Unione Europea - italiano - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibatterici per uso sistemico, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - ceftarolinum fosamilum - polvere per concentrato per soluzione per infusione - preparazione a secco: ceftarolinum fosamilum 600 mg per ceftarolini fosamili monoacetas monohydricus, argininum, per il vetro. - malattie infettive - synthetika